Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
03/08/2026 14:21
BRIEF-U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs) Aug 3 (Reuters) - Zai Lab Ltd 9688.HK:
U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO ZAI LAB’S DLL3-TARGETING ADC ZOCILURTATUG PELITECAN (ZOCI) FOR THE TREATMENT OF NEUROENDOCRINE CARCINOMAS (NECS)
Source text: ID:nBw2B59f5a
Further company coverage: 9688.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows
Brief: Zai Lab Receives U.S. FDA Fast Track Designation For Zocilurtatug Pelitecan (Zoci)